BUZZ-AnaptysBio climbs on arthritis drug trial data

Reuters2025-02-12
BUZZ-AnaptysBio climbs on arthritis drug trial data

** Shares of drug developer AnaptysBio ANAB.O surge 28.3% to $15.88 in morning trade

** Co says its experimental drug, rosnilimab, met the main goal in a mid-stage trial for the treatment of rheumatoid arthritis, a chronic inflammatory disease that primarily affects the joints

** The main goal was to evaluate if the drug could significantly reduce symptoms in three dosages using a tool called DAS-28 CRP score, which measures the severity of the disease after 12 weeks in comparison with placebo

** ANAB says that the drug will be tested in patients with a type of bowel disease called ulcerative colitis by the second quarter of this year

** Stock fell 46% in the last 12 months

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment